Alteration of Pharmacokinetics of Grepafloxacin in Type 2 Diabetic Rats
Purpose. Patients with type 2 diabetes are generally treated with various pharmacological compounds and are exposed to a high risk of drug-drug interactions. However, alterations of pharmacokinetics in a type 2 diabetes model have been obscure. The present study was undertaken to investigate the ef...
Main Authors: | Meguho Watanabe, Masaki Kobayashi, Jiro Ogura, Natsuko Takahashi, Hiroaki Yamaguchi, Ken Iseki |
---|---|
Format: | Article |
Language: | English |
Published: |
Canadian Society for Pharmaceutical Sciences
2014-03-01
|
Series: | Journal of Pharmacy & Pharmaceutical Sciences |
Online Access: | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/21315 |
Similar Items
-
Antibacterial Activity of Grepafloxacin
by: B Wiedemann, et al.
Published: (1998-01-01) -
Crucial residue involved in L-lactate recognition by human monocarboxylate transporter 4 (hMCT4).
by: Shotaro Sasaki, et al.
Published: (2013-01-01) -
Grepafloxacin Clinical Program for Lower Respiratory Tract Infections
by: Arne C Rodloff
Published: (1998-01-01) -
Involvement of Histidine Residue His382 in pH Regulation of MCT4 Activity.
by: Shotaro Sasaki, et al.
Published: (2014-01-01) -
Grepafloxacin Versus Cefixime as Single-Dose Therapy for Uncomplicated Gonorrhea in Women
by: T. F. Mroczkowski, et al.
Published: (1997-01-01)